Skip to main content

Table 4 Efficacy and immune responses of experimental vector vaccines against Mycoplasma hyopneumoniae tested in pigs.

From: Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

Antigen

Vector

Route

Number of vaccinations

Significant decrease of

Humoral response

CMI responsea

Other/comments

References

Lung lesions

Clinical signs

M. hyopneumoniae numbers

Serum

BALFb

NrdF (R2)

S. Typhimurium aroA SL3261c

Oral

2

Yes

  

No

IgA

Yes

Higher ADGb; IgA only after challenge

[94]

P97 (R1R2)

E. rhusiopathiae strain YS-19c

Intranasal

2

Yes

 

Yes

No

 

Yes

 

[95]

P97 (R1R2)

E. rhusiopathiae strain Koganei 65–0.15

Oral

3

Yes

 

No

IgG

IgA

Yes

IgG and IgA only after challenge

[96]

P97 (R1R2)

Adenovirus

Intranasal

2

Yes

 

Yes

IgG, IgA

IgA, IgG (saliva)

Yes

higher ADG; serum inhibited M. hyopneumoniae growth; minor decrease of lung inflammation

Commercial vaccine: no anti-P97 antibodies, better protection

[97]

  1. aCMI responses were tested by stimulation of peripheral blood mononuclear cells (PBMCs) and calculating stimulation indexes.
  2. bBALF, bronchoalveolar lavage fluid; ADG, average daily gain.
  3. cS. Typhimurium: Salmonella Typhimurium; E. rhusiopathiae: Erysipelothrix rhusiopathiae.